In the latest trading session, Adma Biologics (ADMA) closed at $17.59, marking a +1.62% move from the previous day. The stock outpaced the S&P 500's daily loss of 2.06%. Meanwhile, the Dow lost 1.76%, and the Nasdaq, a tech-heavy index, lost 2.39%.
Shares of the infectious disease drug developer have depreciated by 12.93% over the course of the past month, underperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 1.63%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 3.66% rise in the Zacks Consensus EPS estimate. Right now, Adma Biologics possesses a Zacks Rank of #2 (Buy).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 20.36. This signifies a premium in comparison to the average Forward P/E of 18.39 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 38% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
